KT-621, an Oral STAT6 Degrader, Improves Pruritus and Sleep in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 1b Results
September 30, 2026
KT-621, an Oral STAT6 Degrader, Improves Pruritus and Sleep in Patients With Moderate-to-Severe Atopic Dermatitis: Phase 1b Results
European Academy of Dermatology and Venereology Congress (EADV) 2026
Authors: Eric L. Simpson, Alan Irvine, Jared Gollob, Neil Graham, Kelvin Shi, Joyoti Dey, Sagar Agarwal, Anna M. Tallman, Nello Mainolfi
Area of Focus
Immunology
Programs
STAT6 (KT-621)
Indications
Atopic Dermatitis (AD)
Development Stage
Clinical Data
Share
